| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|
J Clin Oncol
|
2005
|
8.87
|
|
2
|
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
|
J Natl Cancer Inst
|
2008
|
3.60
|
|
3
|
Adjuvant docetaxel for high-risk, node-negative breast cancer.
|
N Engl J Med
|
2010
|
2.99
|
|
4
|
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
|
J Clin Oncol
|
2005
|
2.66
|
|
5
|
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
|
BMC Med Genomics
|
2012
|
2.01
|
|
6
|
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
|
Oncologist
|
2012
|
1.96
|
|
7
|
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
|
J Clin Oncol
|
2009
|
1.68
|
|
8
|
[Hemosiderin-laden macrophages count in sputum in diagnosis of dyspnea of heart origin].
|
Med Clin (Barc)
|
2005
|
1.38
|
|
9
|
Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance.
|
Breast Cancer Res Treat
|
2006
|
1.13
|
|
10
|
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
|
J Clin Oncol
|
2005
|
1.06
|
|
11
|
Sleep hypoventilation due to increased nocturnal oxygen flow in hypercapnic COPD patients.
|
Respirology
|
2009
|
1.06
|
|
12
|
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
|
J Clin Oncol
|
2013
|
1.05
|
|
13
|
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register.
|
Breast Cancer Res Treat
|
2010
|
0.97
|
|
14
|
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.95
|
|
15
|
Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.
|
Clin Transl Oncol
|
2012
|
0.95
|
|
16
|
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
|
Breast Cancer Res
|
2013
|
0.93
|
|
17
|
Advanced HER2-positive gastric cancer: current and future targeted therapies.
|
Crit Rev Oncol Hematol
|
2012
|
0.92
|
|
18
|
Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
|
Clin Cancer Res
|
2003
|
0.90
|
|
19
|
Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).
|
Breast Cancer Res Treat
|
2006
|
0.88
|
|
20
|
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
|
Clin Breast Cancer
|
2005
|
0.85
|
|
21
|
Serum markers and prognosis in locally advanced breast cancer.
|
Tumori
|
2006
|
0.84
|
|
22
|
A controlled trial of noninvasive ventilation for chronic obstructive pulmonary disease exacerbations.
|
J Crit Care
|
2009
|
0.83
|
|
23
|
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
|
Cancer
|
2011
|
0.82
|
|
24
|
Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer.
|
Anticancer Drugs
|
2003
|
0.82
|
|
25
|
Guidelines for the management of respiratory complications in patients with neuromuscular disease. Sociedad Española de Neumología y Cirugía Torácica (SEPAR).
|
Arch Bronconeumol
|
2013
|
0.79
|
|
26
|
Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial.
|
Semin Oncol
|
2004
|
0.78
|
|
27
|
Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
|
Anticancer Drugs
|
2004
|
0.76
|
|
28
|
Are daytime arterial blood gases a good reflection of nighttime gas exchange in patients on long-term oxygen therapy?
|
Respir Care
|
2002
|
0.76
|
|
29
|
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
|
Cancer Chemother Pharmacol
|
2010
|
0.76
|
|
30
|
Comprehensive care of amyotrophic lateral sclerosis patients: a care model.
|
Arch Bronconeumol
|
2013
|
0.76
|
|
31
|
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
|
Acta Oncol
|
2008
|
0.75
|
|
32
|
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.
|
Clin Colorectal Cancer
|
2005
|
0.75
|